All News

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The addition of nimotuzumab to a treatment regimen of the chemotherapy gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer.

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

I trusted my oncology team with my life, so it was important that I found doctors I was comfortable with.

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

City of Hope sets the bar for treating people, not just diseases.

Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.

I’m not going to worry that I’m changing my own health by saying out loud that this cancer stuff is hard and scary and kills way too many people every single day.

The Food and Drug Administration granted a fast track designation to PDS0101 plus Keytruda for the treatment of patients with recurrent or metastatic HPV16-related head and neck cancer.

Watching my daughter’s life be interrupted by breast cancer made me want to help other parents who might find themselves in a similar situation.

If approved, Omblastys will be the first FDA-approved drug for children with neuroblastoma that has spread to the central nervous system or leptomeninges.

When I was diagnosed with metastatic breast cancer, my oncology nurse ended up becoming a trusted friend.

After I was diagnosed with cancer, I started to feel like a burden to my loved ones. So, I wrote a letter urging them to continue on with other aspects of their lives.

The FDA approval of Fylnetra, a biosimilar for Neulasta, has the potential to offer patients with cancer a neutropenia treatment option at a lower cost.

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.

The expertise, guidance and overall compassion of Katherine Caprinolo, B.S.N., RN have quite literally helped me survive these past two years.

My worst fear came true: I was diagnosed with COVID-19 while going through cancer. Now I live my life day by day.

A small percentage of patients with metastatic breast cancer participating in clinical trials in the U.S. are Black, which, according to a patient living with the disease is a huge concern since it doesn’t represent the general population.

In the immediate instance — and that’s where life is lived — I won’t spend my energy fighting against cancer. But that does not mean I don’t care.